Literature DB >> 16895045

Evaluating linguistic equivalence of patient-reported outcomes in a cancer clinical trial.

Elizabeth A Hahn1, Rita K Bode, Hongyan Du, David Cella.   

Abstract

BACKGROUND: In order to make meaningful cross-cultural or cross-linguistic comparisons of health-related quality of life (HRQL) or to pool international research data, it is essential to create unbiased measures that can detect clinically important differences. When HRQL scores differ between cultural/linguistic groups, it is important to determine whether this reflects real group differences, or is the result of systematic measurement variability.
PURPOSE: To investigate the linguistic measurement equivalence of a cancer-specific HRQL questionnaire, and to conduct a sensitivity analysis of treatment differences in HRQL in a clinical trial.
METHODS: Patients with newly diagnosed chronic myelogenous leukemia (n = 1049) completed serial HRQL assessments in an international Phase III trial. Two types of differential item functioning (uniform and non-uniform) were evaluated using item response theory and classical test theory approaches. A sensitivity analysis was conducted to compare HRQL between treatment arms using items without evidence of differential functioning.
RESULTS: Among 27 items, nine (33%) did not exhibit any evidence of differential functioning in both linguistic comparisons (English versus French, English versus German). Although 18 items functioned differently, there was no evidence of systematic bias. In a sensitivity analysis, adjustment for differential functioning affected the magnitude, but not the direction or interpretation of clinical trial treatment arm differences. LIMITATIONS: Sufficient sample sizes were available for only three of the eight language groups. Identification of differential functioning in two-thirds of the items suggests that current psychometric methods may be too sensitive.
CONCLUSIONS: Enhanced methodologies are needed to differentiate trivial from substantive differential item functioning. Systematic variability in HRQL across different groups can be evaluated for its effect upon clinical trial results; a practice recommended when data are pooled across cultural or linguistic groups to make conclusions about treatment effects.

Entities:  

Mesh:

Year:  2006        PMID: 16895045     DOI: 10.1191/1740774506cn148oa

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  5 in total

1.  Language-related differential item functioning between English and German PROMIS Depression items is negligible.

Authors:  H Felix Fischer; Inka Wahl; Sandra Nolte; Gregor Liegl; Elmar Brähler; Bernd Löwe; Matthias Rose
Journal:  Int J Methods Psychiatr Res       Date:  2016-10-16       Impact factor: 4.035

2.  Exploring the Score Equivalence of the English and Chinese Versions of the Brief Assessment Scale for Caregivers.

Authors:  Grace Meijuan Yang; Shirlyn Hui-Shan Neo; Irene Teo; Geok Ling Lee; Julian Thumboo; John Chia; Annie Lau; Audrey Koh; Debra Qu; William Wai Lam Che; Hwee Lin Wee; Myra Glajchen; Yin Bun Cheung
Journal:  J Patient Exp       Date:  2019-03-14

3.  The Impact of Cancer Scale (IOC) in Italian long-term cancer survivors: adaptation and psychometric evaluation.

Authors:  Barbara Muzzatti; Cristiana Flaiban; Francesca Romito; Claudia Cormio; Maria Antonietta Annunziata
Journal:  Support Care Cancer       Date:  2013-08-03       Impact factor: 3.603

4.  Race/ethnicity, physical activity, and quality of life in breast cancer survivors.

Authors:  Ashley Wilder Smith; Catherine M Alfano; Bryce B Reeve; Melinda L Irwin; Leslie Bernstein; Kathy Baumgartner; Deborah Bowen; Anne McTiernan; Rachel Ballard-Barbash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

5.  The EORTC emotional functioning computerized adaptive test: phases I-III of a cross-cultural item bank development.

Authors:  Eva-Maria Gamper; Mogens Groenvold; Morten Aa Petersen; Teresa Young; Anna Costantini; Neil Aaronson; Johannes M Giesinger; Verena Meraner; Georg Kemmler; Bernhard Holzner
Journal:  Psychooncology       Date:  2013-11-11       Impact factor: 3.894

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.